Status:
UNKNOWN
Evaluation of the Sensitivity to Different Chemotherapy Regimens in Platinum-Partial Sensitive Recurrent Ovarian Cancer
Lead Sponsor:
Hunan Cancer Hospital
Conditions:
Ovarian Cancer
Eligibility:
All Genders
18-75 years
Phase:
PHASE3
Brief Summary
Multicenter, prospective, randomized studies.Evaluation of the sensitivity to different chemotherapy regimens in platinum-partial sensitive recurrent ovarian cancer based on 11 gene tests of homologou...
Detailed Description
Patients meeting the following inclusion criteria were randomly divided into two groups in a 1:1 ratio: paclitaxel/platinum chemotherapy group (TP) and Doxorubicin Hydrochloride Liposome Injection/pla...
Eligibility Criteria
Inclusion
- age: 18-75 years old
- PS score: ECOG 0 \~ 2
- histopathologically confirmed primary high-grade serous adenocarcinoma or high-grade endometrioid adenocarcinoma of the ovary, fallopian tube or peritoneum;
- the time interval between this recurrence and the last chemotherapy was 6-12 months;
- evaluate the ability of bone marrow, liver, kidney, heart and other important organ functions to withstand chemotherapy;
- expected survival over 3 months;
- sign the informed consent.
Exclusion
- brain metastasis or the presence of symptoms caused by brain metastasis;
- serious complications;
- acute inflammatory reaction;
- other tumors;
- a history of allergy to paclitaxel or polyropyridone liposomes;
Key Trial Info
Start Date :
August 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2021
Estimated Enrollment :
338 Patients enrolled
Trial Details
Trial ID
NCT04337632
Start Date
August 1 2017
End Date
June 1 2021
Last Update
April 8 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hunan Cancer Hospital
Changsha, Hunan, China, 410013